Table 2 Significance of the differences between the control and study groups in the percentage of glomerular area with immunohistochemical expression of ezrin and podocalyxin, estimated by one‐way analysis of variance and Tukey tests.

Ezrin expression	Control	MCD	DMP‐S	DMP‐R	FSGS
Control	—	0.001	0.001	0.001	0.001
MCD	0.001	—	0.001	0.001	0.001
DMP‐S	0.001	0.001	—	0.037	0.001
DMP‐R	0.001	0.001	0.037	—	0.068
FSGS	0.001	0.001	0.001	0.068	—

DMP‐R, diffuse mesengial proliferation‐resistant; DMP‐S, diffuse mesengial proliferation‐sensitivity; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; —, absence of the trait in the given group.